Interstitial lung disease in systemic sclerosis

Seminars in Respiratory and Critical Care Medicine

Volumn 35, Issue 2, 2014, Pages 213-221

  Wells, Athol U ^a   Margaritopoulos, George A ^b   Antoniou, Katerina M ^b   Denton, Chris ^c  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CRETE   (Greece)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

cyclophosphamide; high resolution computed tomography; interstitial lung disease; pulmonary function tests; systemic sclerosis

Indexed keywords

ANTINUCLEAR ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HLA ANTIGEN; INTERLEUKIN 1BETA; RITUXIMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DISEASE COURSE; DISEASE SEVERITY; DYSPNEA; ENVIRONMENTAL FACTOR; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENETIC ASSOCIATION; GOLD STANDARD; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; LUNG LAVAGE; OCCUPATIONAL EXPOSURE; PATHOGENESIS; PLETHYSMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RESPIRATORY FAILURE; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC SCLEROSIS; THORAX RADIOGRAPHY; TREATMENT RESPONSE; COMPLICATION; LUNG DISEASES, INTERSTITIAL; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; PROGNOSIS; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84897045933     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0034-1371541     Document Type: Article

References (58)

1. Chifflot H., Fautrel B., Sordet C., Chatelus E., Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum: 2008; 37 4 223 235
2. American Thoracic Society; European Respiratory Society American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med: 2002; 165 2 277 304
3. Tyndall A. J., Bannert B., Vonk M., et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis: 2010; 69 10 1809 1815
4. Steen V. D., Conte C., Owens G. R., Medsger T. A. Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum: 1994; 37 9 1283 1289 (Pubitemid 24320744)
5. Mayes M. D., Lacey J. V. Jr, Beebe-Dimmer J., et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum: 2003; 48 8 2246 2255 (Pubitemid 36959206)
6. Reveille J. D. Ethnicity and race and systemic sclerosis: how it affects susceptibility, severity, antibody genetics, and clinical manifestations. Curr Rheumatol Rep: 2003; 5 2 160 167
7. D'Angelo W. A., Fries J. F., Masi A. T., Shulman L. E. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med: 1969; 46 3 428 440
8. Bouros D., Wells A. U., Nicholson A. G., et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med: 2002; 165 12 1581 1586 (Pubitemid 34693935)
9. Launay D., Remy-Jardin M., Michon-Pasturel U., et al. High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol: 2006; 33 9 1789 1801 (Pubitemid 44373213)
10. De Santis M., Bosello S., La Torre G., et al. Functional, radiological and biological markers of alveolitis and infections of the lower respiratory tract in patients with systemic sclerosis. Respir Res: 2005; 6 96
11. Desai S. R., Veeraraghavan S., Hansell D. M., et al. CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology: 2004; 232 2 560 567 (Pubitemid 38971300)
12. Wells A. U., Cullinan P., Hansell D. M., et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med: 1994; 149 6 1583 1590 (Pubitemid 24175979)
13. Daniil Z. D., Gilchrist F. C., Nicholson A. G., et al. A histologic pattern of nonspecific interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med: 1999; 160 3 899 905 (Pubitemid 29442028)
14. Kocheril S. V., Appleton B. E., Somers E. C., et al. Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia. Arthritis Rheum: 2005; 53 4 549 557 (Pubitemid 41282803)
15. Tashkin D. P., Elashoff R., Clements P. J., et al. Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med: 2006; 354 25 2655 2666
16. Goh N. S., Desai S. R., Veeraraghavan S., et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med: 2008; 177 11 1248 1254 (Pubitemid 351860934)
17. Walker U. A., Tyndall A., Czirják L., et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis: 2007; 66 6 754 763 (Pubitemid 46846694)
18. Briggs D. C., Vaughan R. W., Welsh K. I., Myers A., duBois R. M., Black C. M. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet: 1991; 338 8768 661 662
19. Gilchrist F. C., Bunn C., Foley P. J., et al. Class II HLA associations with autoantibodies in scleroderma: a highly significant role for HLA-DP. Genes Immun: 2001; 2 2 76 81 (Pubitemid 33674232)
20. Kuwana M., Kaburaki J., Mimori T., Kawakami Y., Tojo T. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum: 2000; 43 5 1074 1084 (Pubitemid 30368188)
21. Hu P. Q., Fertig N., Medsger T. A. Jr, Wright T. M. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum: 2003; 48 5 1363 1373 (Pubitemid 36554535)
22. Reveille J. D., Solomon D. H.; American College of Rheumatology Ad Hoc Committee of Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum: 2003; 49 3 399 412 (Pubitemid 36682409)
23. Feghali-Bostwick C., Medsger T. A. Jr, Wright T. M. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum: 2003; 48 7 1956 1963 (Pubitemid 36828691)
24. Zhou X., Tan F. K., Wang N., et al. Genome-wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high disease prevalence. Arthritis Rheum: 2003; 48 9 2585 2592 (Pubitemid 37129435)
25. Allanore Y., Dieude P., Boileau C. Genetic background of systemic sclerosis: autoimmune genes take centre stage. Rheumatology (Oxford): 2010; 49 2 203 210
26. Kawaguchi Y., Tochimoto A., Ichikawa N., et al. Association of IL1A gene polymorphisms with susceptibility to and severity of systemic sclerosis in the Japanese population. Arthritis Rheum: 2003; 48 1 186 192 (Pubitemid 36091662)
27. Beretta L., Bertolotti F., Cappiello F., et al. Interleukin-1 gene complex polymorphisms in systemic sclerosis patients with severe restrictive lung physiology. Hum Immunol: 2007; 68 7 603 609 (Pubitemid 46920553)
28. Sumita Y., Sugiura T., Kawaguchi Y., et al. Genetic polymorphisms in the surfactant proteins in systemic sclerosis in Japanese: T/T genotype at 1580 C/T (Thr131Ile) in the SP-B gene reduces the risk of interstitial lung disease. Rheumatology (Oxford): 2008; 47 3 289 291 (Pubitemid 351267193)
29. Standardized lung function testing. Official statement of the European Respiratory Society. Eur Respir J Suppl: 1993; 16 1 100
30. Wells A. U., King A. D., Rubens M. B., Cramer D., du Bois R. M., Hansell D. M. Lone cryptogenic fibrosing alveolitis: a functional-morphologic correlation based on extent of disease on thin-section computed tomography. Am J Respir Crit Care Med: 1997; 155 4 1367 1375 (Pubitemid 27172785)
31. Nathan S. D., Shlobin O. A., Ahmad S., Urbanek S., Barnett S. D. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest: 2007; 131 3 657 663 (Pubitemid 46446854)
32. Steen V. D., Graham G., Conte C., Owens G., Medsger T. A. Jr. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum: 1992; 35 7 765 770
33. Hughes J. MB, Pride N. B. Examination of the carbon monoxide diffusing capacity (DL(CO)) in relation to its KCO and VA components. Am J Respir Crit Care Med: 2012; 186 2 132 139
34. Schurawitzki H., Stiglbauer R., Graninger W., et al. Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography. Radiology: 1990; 176 3 755 759 (Pubitemid 20266769)
35. Wells A. U., Rubens M. B., du Bois R. M., Hansell D. M. Serial CT in fibrosing alveolitis: prognostic significance of the initial pattern. AJR Am J Roentgenol: 1993; 161 6 1159 1165 (Pubitemid 24008055)
36. Shah R. M., Jimenez S., Wechsler R. Significance of ground-glass opacity on HRCT in long-term follow-up of patients with systemic sclerosis. J Thorac Imaging: 2007; 22 2 120 124 (Pubitemid 46868280)
37. Wells A. U. Forced vital capacity as a primary end point in idiopathic pulmonary fibrosis treatment trials: making a silk purse from a sow's ear. Thorax: 2013; 68 4 309 310
38. Ohnishi H., Yokoyama A., Kondo K., et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med: 2002; 165 3 378 381 (Pubitemid 34118512)
39. Hasegawa M., Fujimoto M., Hamaguchi Y., et al. Use of serum clara cell 16-kDa (CC16) levels as a potential indicator of active pulmonary fibrosis in systemic sclerosis. J Rheumatol: 2011; 38 5 877 884
40. Bonella F., Volpe A., Caramaschi P., et al. Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement. Sarcoidosis Vasc Diffuse Lung Dis: 2011; 28 1 27 33
41. De Lauretis A., Sestini P., Pantelidis P., et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol: 2013; 40 4 435 446
42. Goh N. S., Desai S. R., Anagnostopoulos C., et al. Increased epithelial permeability in pulmonary fibrosis in relation to disease progression. Eur Respir J: 2011; 38 1 184 190
43. Goh N. S., Veeraraghavan S., Desai S. R., et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum: 2007; 56 6 2005 2012 (Pubitemid 47110399)
44. Strange C., Bolster M. B., Roth M. D., et al. Scleroderma Lung Study Research Group. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med: 2008; 177 1 91 98
45. Hoyles R. K., Ellis R. W., Wellsbury J., et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum: 2006; 54 12 3962 3970 (Pubitemid 44955900)
46. Seibold J. R., Denton C. P., Furst D. E., et al. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum: 2010; 62 7 2101 2108
47. Kowal-Bielecka O., Landewé R., Avouac J., et al. EUSTAR Co-Authors. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis: 2009; 68 5 620 628
48. Tashkin D. P., Elashoff R., Clements P. J., et al. Scleroderma Lung Study Research Group. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med: 2007; 176 10 1026 1034 (Pubitemid 350127847)
49. White B., Moore W. C., Wigley F. M., Xiao H. Q., Wise R. A. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med: 2000; 132 12 947 954 (Pubitemid 30397594)
50. Fischer A., Brown K. K., Du Bois R. M., et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol: 2013; 40 5 640 646
51. Steen V. D., Medsger T. A. Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum: 1998; 41 9 1613 1619 (Pubitemid 28459919)
52. DeMarco P. J., Weisman M. H., Seibold J. R., et al. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum: 2002; 46 11 2983 2989 (Pubitemid 35315892)
53. Demedts M., Behr J., Buhl R., et al. IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med: 2005; 353 21 2229 2242 (Pubitemid 41697286)
54. Noble P. W., Albera C., Bradford W. Z., et al. CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet: 2011; 377 9779 1760 1769
55. Burt R. K., Shah S. J., Dill K., et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet: 2011; 378 9790 498 506
56. Nash R. A., McSweeney P. A., Crofford L. J., et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood: 2007; 110 4 1388 1396 (Pubitemid 47281441)
57. Daoussis D., Liossis S. N., Tsamandas A. C., et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford): 2010; 49 2 271 280
58. Daoussis D., Liossis S. N., Tsamandas A. C., et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol: 2012; 30 (2, Suppl 71): S17 S22